

# Zeina Ghorab

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1474123/publications.pdf>

Version: 2024-02-01

13  
papers

61  
citations

1937685

4  
h-index

1588992

8  
g-index

13  
all docs

13  
docs citations

13  
times ranked

92  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Comparison of ACR-TIRADS to the ATA Guidelines for Thyroid Nodules: A Neck to Neck Comparison. , 2022, 1, 1-8.   |     | 1         |
| 2  | Cytologyâ€based screening for anal intraepithelial neoplasia in women with a history of cervical intraepithelial neoplasia or cancer. Cancer Cytopathology, 2021, 129, 140-147.  | 2.4 | 11        |
| 3  | Preâ€operative diagnosis of a Brunner's gland hamartoma by endoscopic ultrasoundâ€guided fine needle aspiration. Cytopathology, 2021, 32, 674-676.   | 0.7 | 1         |
| 4  | Breast implant-associated EBV-positive diffuse large B-cell lymphoma: Two case reports and literature review. Pathology Research and Practice, 2021, 226, 153589.  | 2.3 | 12        |
| 5  | Horner syndrome secondary to Hodgkin lymphoma. Cmaj, 2020, 192, E187-E187.   | 2.0 | 2         |
| 6  | Autologous stem cell transplant and combination immunotherapy of rituximab and interferonâ€± induces prolonged clinical and molecular remissions in patients with follicular lymphoma. British Journal of Haematology, 2019, 184, 469-472.   | 2.5 | 4         |
| 7  | Management of newly diagnosed highâ€risk and intermediateâ€risk follicular lymphoma with <sup>90</sup>Y ibritumomab tiuxetan in a phase II study. Hematological Oncology, 2018, 36, 525-532.   | 1.7 | 4         |
| 8  | <scp>S</scp>erumâ€derived carcinoembryonic antigen (<scp>CEA</scp>) activates fibroblasts to induce a local reâ€modeling of the extracellular matrix that favors the engraftment of <scp>CEA</scp>-expressing tumor cells. International Journal of Cancer, 2018, 143, 1963-1977.  | 5.1 | 18        |
| 9  | A Challenging Diagnosis of IgG4-Related Disease When Understanding Limitations of Laboratory Testing Was Pivotal. Case Reports in Medicine, 2017, 2017, 1-5.   | 0.7 | 4         |
| 10 | Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan. Blood, 2016, 128, 1794-1794.   | 1.4 | 0         |
| 11 | Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors &gt;1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab. Blood, 2012, 120, 3681-3681.  | 1.4 | 0         |
| 12 | First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan (90Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma. Blood, 2011, 118, 2701-2701. | 1.4 | 0         |
| 13 | Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.. Blood, 2006, 108, 3067-3067.   | 1.4 | 4         |